5365-23-1

Basic information

• Product Name: (2,2-DICHLOROCYCLOPROPYL)METHANOL
• Synonyms: (2,2-DICHLOROCYCLOPROPYL)METHANOL;1,1-Dichloro-2-(hydroxymethyl)cyclopropane;2,2-Dichloro-1-(hydroxymethyl)cyclopropane;2,2-Dichlorocyclopropanemethanol
• CAS NO: 5365-23-1
• Molecular Formula: C₄H₆Cl₂O
• Molecular Weight: 141
• Mol File: 5365-23-1.mol

Chemical Properties

• Boiling Point: 82-85℃
• Flash Point: 98 °C
• Appearance: White solide
• Density: 1.44 g/cm³
• Refractive Index: 1.4870 (20℃)
• PKA: 15.10±0.10(Predicted)
• CAS DataBase Reference: (2,2-DICHLOROCYCLOPROPYL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (2,2-DICHLOROCYCLOPROPYL)METHANOL(5365-23-1)
• EPA Substance Registry System: (2,2-DICHLOROCYCLOPROPYL)METHANOL(5365-23-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 5365-23-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2,2-Dichlorocyclopropyl)methanol is used as a building block in organic synthesis for the creation of various chemical compounds. Its unique cyclopropane structure and reactivity make it a valuable component in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
(2,2-Dichlorocyclopropyl)methanol is used as a reagent in medicinal chemistry for the development of new pharmaceutical products. Its potential use in the synthesis of various drugs highlights its importance in the discovery and production of novel therapeutic agents.
Used in Pharmaceutical Applications:
(2,2-Dichlorocyclopropyl)methanol is used as an intermediate in the synthesis of various drugs, contributing to the development of new medications with potential therapeutic benefits. Its role in drug synthesis underscores its significance in advancing pharmaceutical research and innovation.
Used in Chemical and Pharmaceutical Product Development:
(2,2-Dichlorocyclopropyl)methanol plays a crucial role in the development of new chemical and pharmaceutical products. Its versatility and reactivity in organic synthesis and medicinal chemistry make it an essential compound for researchers and chemists working in these fields.

Upstream product

• 64794-13-4 Acetaldehyd-2,2-dichlorcyclopropylmethyl-ethylacetal 
• 64794-14-5 1,1-bis<(2,2-dichlorocyclopropyl)methoxy>ethane 
• 5365-14-0 2,2-dichlorocyclopropanecarboxylic acid 
• 119060-47-8 tert-Butyl 2,2-dichlorocyclopropanecarboxylate 
• 72733-56-3 propionic acid 2,2-dichlorocyclopropylmethane ester 
• 22084-97-5 1,1-Dichlor-2-trimethylsiloxymethyl-cyclopropan 

Downstream Products

• 5365-14-0 2,2-dichlorocyclopropanecarboxylic acid 
• 89723-51-3 (2-Chlorocyclopropyl)carbinol 
• 89723-51-3 trans-(2-Chlorocyclopropyl)carbinol 
• 89723-51-3 cis-(2-Chlorocyclopropyl)carbinol 
• 6061-06-9 1,1-dichlorobuta-1,3-diene 
• 316377-54-5 (+)-(S)-2,2-dichlorocyclopropanemethanol 

Relevant articles and documents

MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce excessive activation of complement.

ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS

The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Reduction of Cyclopropanecarboxylic Acids by Borane, a Chemoselective Reaction Sensitive to Steric Interactions and Reaction Conditions

A number of cyclopropanecarboxylic acids have been reduced by borane in tetrahydrofuran to the corresponding cyclopropyl alcohols. The yield was sensitive to the steric influence of the substituents attached to the ring, the reaction temperature, and the

Synthetic studies on the trans-chlorocyclopropane dienyne side chain of callipeltoside A.

[structure] Enantiomerically enriched trans-chlorocyclopropanemethanol was obtained by lipase kinetic resolution of dichlorocyclopropanemethanol 3, followed by reduction. The sp-sp(2) bond of the trans-chlorocyclopropane dienyne side chain of callipeltoside A was constructed via a Stille coupling reaction of 1, 1-dibromo-1-alkene 7 and a vinylstannane in a highly dipolar solvent capable of promoting HBr elimination to give internal alkynes.